@import url(http://markets.financialcontent.com/client/gatehouse/privatelabel.css);
Merck To Jointly Develop EC145 With Endocyte

Merck & Co. Inc. (NYSE: MRK) and Endocyte Inc. (Nasdaq: ECYT) will jointly develop and commercialize Endocyte's late stage cancer drug candidate EC145. Shares of Merck rose 21 cents to $37.99 while Endocyte stock more than doubled by surging $3.88 to $7.68.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here